



ACIP Meningococcal Vaccines Work Group Introduction

Katherine Poehling, MD, MPH
Chair, ACIP Meningococcal Vaccines Work Group

October 25, 2023

Meningococcal Vaccines Work Group

- ACIP Members on the WG
 - Katherine Poehling (Chair)
 - Lynn Bahta
 - Jamie Loehr

- Ex Officio WG Members
 - Margaret Bash (FDA)
 - Mark Connelly (FDA)
 - Francisco Leyva (NIH)

- WG Liaisons and Consultants
 - Amra Resic (AAFP)
 - Samir Shah (AAP)
 - Sharon McMullen (ACHA)
 - Cacky Tate / Karyn Lyons (AIM)
 - Paul Cieslak (CSTE)
 - Kathy Hsu (IDSA)
 - Joseline Zafack (NACI)
 - Jeff Goad (NFID)
 - Jessica Cataldi (PIDS)
 - Amy Middleman (SAHM)
 - David Stephens (Emory)

- CDC Contributors
 - Jennifer Collins (DBD/NCIRD)
 - Sam Crowe (DBD/NCIRD)
 - Lucy McNamara (DBD/NCIRD)
 - Ismael Ortega-Sanchez (DVD/NCIRD)
 - Andrew Leidner (ISD/NCIRD)
 - LeAnne Fox (DBD/NCIRD)
 - Susan Hariri (DBD/NCIRD)
 - Amy Rubis (DBD/NCIRD)
 - Noele Nelson (DBD/NCIRD)
 - Alison Albert (DBD/NCIRD)
 - Angela Jiles (DBD/NCIRD)
 - Jonathan Duffy (DHQP/NCEZID)
 - Tanya Myers (DHQP/NCEZID)
 - Liz Velazquez (ISD/NCIRD)
 - Jessica MacNeil (ACIP Secretariat)
 - Melinda Wharton (ACIP Secretariat)

- GRADE/EtR Support
 - Doug Campos-Outcalt (Arizona)
 - Rebecca Morgan (Case Western Reserve)

Policy topics under consideration by Work Group regarding Pfizer's pentavalent vaccine

- Should pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both vaccines?
- Should pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only?
- Should pentavalent vaccine be included as an option for people currently recommended to receive MenB only?

Summary of ACIP meetings

- February 2023
 - Epidemiology of meningococcal disease in the United States
 - Pfizer's MenABCWY vaccine clinical trials data
 - Work group interpretation of Pfizer's MenABCWY trials data
- June 2023
 - CDC's cost effectiveness model
 - Summary of GRADE and EtR framework

Meningococcal Work Group Meeting Review

June–October 2023

- Feedback from June ACIP meeting
 - Review of meningococcal schedule postponed to allow for consideration of GSK’s forthcoming pentavalent vaccine and availability of data about post-COVID meningococcal epidemiology
- Comparisons of cost-effectiveness models
- Updates on CDC cost-effectiveness model with new price estimate
 - Price for pentavalent **was ~\$40–90 more than MenB and now is similar**
- Discussed 3 potential recommendation options based on concerns raised by ACIP members in June and new cost-effectiveness estimates

Work Group determinations for policy questions

- Should the pentavalent vaccine be included as an option for MenACWY/MenB vaccination in people currently recommended to receive both vaccines?
 - **YES (strong consensus)**
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenACWY only?
 - **NO (strong consensus)**
- Should the pentavalent vaccine be included as an option for people currently recommended to receive MenB only?
 - **Perhaps (limited consensus)**

Today's agenda

■ Meningococcal Vaccines Session

Topic	Presenter
Plan for revisiting the adolescent schedule for meningococcal vaccines	Dr. Lucy McNamara (CDC/NCIRD)
Comparison of Pfizer and CDC cost effectiveness analyses for Pfizer's MenABCWY vaccine	Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Summary of EtR and proposed recommendations for Pfizer's MenABCWY vaccine	Dr. Jennifer Collins (CDC/NCIRD)
Vaccines for Children Resolution	Dr. Jeanne Santoli (CDC/NCIRD)

■ Later today

- Meningococcal vote regarding Pfizer's MenABCWY vaccine
- Meningococcal VFC vote regarding Pfizer's MenABCWY vaccine